Your cravings are a brain problem. We treat the brain.
The iControl Weight Loss Program uses Naltrexone and Bupropion to modify the way your brain's reward and hunger systems respond to food — making it easier to resist cravings, reduce appetite, and sustain the results you achieve. No surgery. Pharmaceutical treatment for the biology of obesity.
Most diets fail because they fight the brain. iControl changes the brain.
The reason strict diets rarely work long-term is neurological — the brain's reward system works against caloric restriction. iControl targets this directly, modifying how the pleasure center responds to food consumption.
The brain's reward system — the same pathway activated by addictive substances — responds to certain foods by triggering compulsive cravings. Naltrexone, an opioid antagonist, blocks these receptors without activating them — inhibiting the reward signal that drives food cravings. The result is that the compulsion to eat chips or donuts when your brain signals you to do so becomes significantly less powerful.
Obesity from acute stress and emotional eating responds particularly well to the Naltrexone-Bupropion combination because both medications address the neurological drivers of stress-induced food-seeking behavior. Whether your weight gain is driven by genetics, stress, or both — the iControl program is designed to modify the hunger system regardless of its original cause.
Bupropion is an antidepressant that has been used for mild-to-severe depressive disorders for many years. In obesity treatment, it affects the food reward center and reduces appetite — but for patients where low mood and weight gain are intertwined, Bupropion addresses both simultaneously. Many patients find that the mood improvement from Bupropion makes the weight loss program significantly easier to adhere to.
The most common reason diets fail is not lack of knowledge — it is the brain's reward system working against sustained dietary restriction. iControl is specifically designed for patients who know how to eat well but cannot sustain it because their brain's pleasure center overrides their intentions. The program changes the neurological dynamic rather than asking for more willpower.
For patients with general obesity — regardless of the cause — iControl provides a pharmaceutical framework that makes behavior change achievable. One out of three adults in the US has excess weight. Many maintain unhealthy eating habits that put them at risk of diabetes, heart attack, and stroke. The iControl program addresses the neurological root of these habits.
Low-dose Naltrexone is prescribed for alcohol addiction — and its inhibition effects on the opioid reward pathway carry over to food cravings through the same mechanism. For patients with a history of addictive behavior patterns — including food addiction — Naltrexone's receptor-blocking effect addresses the craving mechanism at its neurological source.
Obesity doesn't define you — but the brain's reward system may be working against you. iControl changes that equation.
Before starting the iControl program, consultation with one of our providers is required. Not all patients can be prescribed Naltrexone and Bupropion — contraindications include cardiovascular diseases, diabetes, and seizure disorders. We confirm your candidacy before recommending the program.
Two medications. One system. Your food reward center.
The iControl Weight Loss Program combines two pharmaceutical agents that work synergistically on the brain's hunger and reward systems. Naltrexone is an opioid antagonist — it acts on opioid receptors without activating them, blocking the reward signal that those receptors produce in response to food. This is the same mechanism used to treat alcohol and opioid addiction — Naltrexone inhibits the neurological reward that drives compulsive consumption, whether the trigger is alcohol or calorie-dense food.
Bupropion is an antidepressant and smoking cessation medication that acts on dopamine and norepinephrine pathways. In obesity treatment, it affects the food reward center and reduces appetite through its action on the hypothalamus — the brain region that controls hunger and satiety signaling. In combination, Naltrexone and Bupropion create a synergistic effect that is significantly more powerful than either medication alone — they are the active components of FDA-approved combination weight loss medication.
The key difference from diet-based approaches is mechanism: iControl doesn't ask you to use willpower against your brain's reward system — it changes how your brain's reward system responds to food. For patients whose weight is driven by the neurological dynamics of craving and reward rather than simply caloric math, this is a fundamentally different — and more effective — intervention.
Contraindications include: cardiovascular diseases, uncontrolled hypertension, type 2 diabetes (depending on medications), seizure disorders, eating disorders (bulimia/anorexia), current use of opioid medications, and pregnancy. A physician consultation is mandatory before starting the iControl program. We assess your complete medical history and confirm candidacy before prescribing.
The most promising pharmaceutical treatment for neurological obesity.
For patients whose weight is driven by the brain's reward system rather than simple caloric imbalance, pharmaceutical modification of that system is more effective than behavioral intervention alone. The Naltrexone-Bupropion combination targets the neurological root of food cravings.
From fighting cravings to controlling them.
A mandatory consultation with one of our providers before starting the program. We review your health history, confirm candidacy, and check for contraindications — cardiovascular disease, seizure disorders, current medications, and other factors that affect whether Naltrexone-Bupropion is appropriate for you.
Naltrexone and Bupropion prescribed at doses appropriate for your weight management goals. Dose is typically titrated upward to minimize side effects during adjustment. Most patients are on the full protocol within 4 weeks.
The medications make resisting cravings significantly easier — we build on this with guidance on food choices and eating patterns. The goal is to use the window of reduced craving to establish the habits that make results lasting after the pharmaceutical support is tapered.
Regular check-ins throughout the program. Weight, side effects, and response assessed. The program is adjusted based on your individual response to the medication and the behavioral changes you're making.
Medicine that
gets you.
iControl modifies the neurological system that makes dieting so hard. Our physicians assess candidacy carefully and supervise the program throughout — because getting the pharmacology right is everything.
Treats the Cause, Not the Symptom
Most weight loss programs treat appetite with restriction. iControl treats the neurological reward system that drives appetite — the root cause for patients whose overeating is driven by craving rather than hunger.
Mandatory Candidacy Assessment
We don't prescribe Naltrexone-Bupropion without a thorough consultation. The contraindications are real and important. We confirm you're an appropriate candidate before starting — and if you're not, we recommend a better-suited program.
Body Transformation Without Surgery
Visit Iuventus and start your body transformation without surgeries. The iControl program provides pharmaceutical-level intervention for obesity with the access and convenience of an outpatient clinic.
Addresses Co-Occurring Conditions
For patients with depression alongside obesity — a common combination — Bupropion's antidepressant effect works simultaneously with its weight-loss mechanism. A single pharmaceutical intervention that addresses two intertwined conditions.
Cravings controlled.
Weight lost..
Everything you
want to know.
Start the life
you've always wanted.
A mandatory medical consultation before starting — we confirm candidacy, review contraindications, and design the program around your specific situation. Iuventus Medical Center Las Vegas.